View Item 

Show simple item record

Variability in Glucocorticoid Prescribing for Rheumatoid Arthritis and the Influence of Provider Preference on Long‐Term Use of Glucocorticoids
dc.contributor.authorGeorge, Michael D.
dc.contributor.authorBaker, Joshua F.
dc.contributor.authorWallace, Beth
dc.contributor.authorChen, Lang
dc.contributor.authorWu, Qufei
dc.contributor.authorXie, Fenglong
dc.contributor.authorYun, Huifeng
dc.contributor.authorCurtis, Jeffrey R.
dc.date.accessioned2021-12-02T02:31:13Z
dc.date.available2022-12-01 21:31:13en
dc.date.available2021-12-02T02:31:13Z
dc.date.issued2021-11
dc.identifier.citationGeorge, Michael D.; Baker, Joshua F.; Wallace, Beth; Chen, Lang; Wu, Qufei; Xie, Fenglong; Yun, Huifeng; Curtis, Jeffrey R. (2021). "Variability in Glucocorticoid Prescribing for Rheumatoid Arthritis and the Influence of Provider Preference on Long‐Term Use of Glucocorticoids." Arthritis Care & Research (11): 1597-1605.
dc.identifier.issn2151-464X
dc.identifier.issn2151-4658
dc.identifier.urihttps://hdl.handle.net/2027.42/171024
dc.publisherWiley Periodicals, Inc.
dc.titleVariability in Glucocorticoid Prescribing for Rheumatoid Arthritis and the Influence of Provider Preference on Long‐Term Use of Glucocorticoids
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelGeriatrics
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171024/1/acr24382_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171024/2/acr24382.pdf
dc.identifier.doi10.1002/acr.24382
dc.identifier.sourceArthritis Care & Research
dc.identifier.citedreferenceWallace BI, Lin P, Kamdar N, Noureldin M, Hayward R, Fox DA, et al. Patterns of glucocorticoid prescribing and provider‐level variation in a commercially insured incident rheumatoid arthritis population: a retrospective cohort study. Semin Arthritis Rheum 2020; 50: 228 – 36.
dc.identifier.citedreferenceGrijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, et al. Initiation of tumor necrosis factor‐α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011; 306: 2331 – 9.
dc.identifier.citedreferenceDixon WG, Abrahamowicz M, Beauchamp ME, Ray DW, Bernatsky S, Suissa S, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case‐control analysis. Ann Rheum Dis 2012; 71: 1128 – 33.
dc.identifier.citedreferenceAu K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 785 – 91.
dc.identifier.citedreferenceSmitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 2008; 35: 387 – 93.
dc.identifier.citedreferenceWolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease‐modifying antirheumatic drugs, and anti–tumor necrosis factor therapy. Arthritis Rheum 2006; 54: 628 – 34.
dc.identifier.citedreferenceWeaver A, Troum O, Hooper M, Koenig AS, Chaudhari S, Feng J, et al. Rheumatoid arthritis disease activity and disability affect the risk of serious infection events in RADIUS 1. J Rheumatol 2013; 40: 1275 – 81.
dc.identifier.citedreferenceSingh JA, Saag KG, Bridges Jr SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016; 68: 1 – 26.
dc.identifier.citedreferenceSmolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease‐modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017; 76: 960 – 77.
dc.identifier.citedreferenceAlbrecht K, Krüger K, Wollenhaupt J, Alten R, Backhaus M, Baerwald C, et al. German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease‐modifying antirheumatic drugs. Rheumatol Int 2014; 34: 1 – 9.
dc.identifier.citedreferenceCaplan L, Wolfe F, Russell AS, Michaud K. Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. J Rheumatol 2007; 34: 696 – 705.
dc.identifier.citedreferenceMakol A, Davis III JM, Crowson CS, Therneau TM, Gabriel SE, Matteson EL. Time trends in glucocorticoid use in rheumatoid arthritis: results from a population‐based inception cohort, 1980–1994 versus 1995–2007. Arthritis Care Res (Hoboken) 2014; 66: 1482 – 8.
dc.identifier.citedreferenceThiele K, Buttgereit F, Huscher D, Zink A, German Collaborative Arthritis Centres. Current use of glucocorticoids in patients with rheumatoid arthritis in Germany. Arthritis Rheum 2005; 53: 740 – 7.
dc.identifier.citedreferenceBrookhart MA, Wang PS, Solomon DH, Schneeweiss S. Evaluating short‐term drug effects using a physician‐specific prescribing preference as an instrumental variable. Epidemiol Camb Mass 2006; 17: 268 – 75.
dc.identifier.citedreferenceCenters for Medicare & Medicaid Services. Brief summaries of Medicare & Medicaid. 2015. URL: http://www.cms.gov/Research‐Statistics‐Data‐and‐Systems/Statistics‐Trends‐and‐Reports/MedicareProgramRatesStats/SummaryMedicareMedicaid.html.
dc.identifier.citedreferenceAmerican Medical Association. AMA Physician Masterfile. URL: https://www.ama‐assn.org/practice‐management/masterfile/ama‐physician‐masterfile.
dc.identifier.citedreferenceBlack RJ, Joseph RM, Brown B, Movahedi M, Lunt M, Dixon WG. Half of U.K. patients with rheumatoid arthritis are prescribed oral glucocorticoid therapy in primary care: a retrospective drug utilisation study. Arthritis Res Ther 2015; 17: 375.
dc.identifier.citedreferenceCriswell LA, Redfearn WJ. Variation among rheumatologists in the use of prednisone and second‐line agents for the treatment of rheumatoid arthritis. Arthritis Rheum 1994; 37: 476 – 80.
dc.identifier.citedreferenceBlack RJ, Lester S, Buchbinder R, Barrett C, Lassere M, March L, et al. Factors associated with oral glucocorticoid use in patients with rheumatoid arthritis: a drug use study from a prospective national biologics registry. Arthritis Res Ther 2017; 19: 253.
dc.identifier.citedreferenceGeorge MD, Sauer BC, Teng CC, Cannon GW, England BR, Kerr GS, et al. Biologic and glucocorticoid use after methotrexate initiation in patients with rheumatoid arthritis. J Rheumatol 2019; 46: 343 – 50.
dc.identifier.citedreferenceCenters for Medicare and Medicaid Services Quality Payment Program. MIPS Quality ID #180: Rheumatoid arthritis (RA): glucocorticoid management. URL: https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM‐Measures/2019_Measure_180_MIPSCQM.pdf.
dc.identifier.citedreferenceBrookhart MA, Rassen JA, Schneeweiss S. Instrumental variable methods in comparative safety and effectiveness research. Pharmacoepidemiol Drug Saf 2010; 19: 537 – 54.
dc.identifier.citedreferenceBakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E, et al. Low‐dose prednisone inclusion in a methotrexate‐based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 2012; 156: 329 – 39.
dc.identifier.citedreferenceSvensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafström I, for the BARFOT Study Group. Low‐dose prednisolone in addition to the initial disease‐modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two‐year randomized trial. Arthritis Rheum 2005; 52: 3360 – 70.
dc.identifier.citedreferenceButtgereit F, Mehta D, Kirwan J, Szechinski J, Boers M, Alten RE, et al. Low‐dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA‐2). Ann Rheum Dis 2013; 72: 204 – 10.
dc.identifier.citedreferenceMahajan T, O’Dell JR. It is the best of treatments, it is the worst of treatments: the continuing love‐hate relationship with glucocorticoids in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2017; 69: 1131 – 3.
dc.identifier.citedreferenceStrehl C, Bijlsma JW, de Wit M, Boers M, Caeyers N, Cutolo M, et al. Defining conditions where long‐term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis 2016; 75: 952 – 7.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
acr24382_am.pdf
Size:
353.7KB
Format:
PDF
View/Open
Name:
acr24382.pdf
Size:
499.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.